EPITOPE INC/OR/
15-12G, 2000-10-03
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: SED INTERNATIONAL HOLDINGS INC, S-8, EX-23, 2000-10-03
Next: AMPLICON INC, NTN 10K, 2000-10-03



                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                     FORM 15


CERTIFICATION  AND NOTICE OF TERMINATION OF REGISTRATION  UNDER SECTION 12(g) OF
THE SECURITIES  EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

                                                  COMMISSION FILE NUMBER 1-10492

                                  EPITOPE, INC.
             (Exact name of registrant as specified in its charter)

                            8505 S.W. Creekside Place
                             Beaverton, Oregon 97008
                                 (503) 641-6115
   (Address, including zip code, and telephone number, including area code, of
                    registrant's principal executive offices)

                           Common Stock, no par value
                         Preferred Stock Purchase Rights
            (Title of each class of securities covered by this Form)

                                      NONE
   (Title of all other classes of securities for which a duty to file reports
                      under Section 13(a) or 15(d) remains)

        Please  place an X in the  box(es) to  designate  the  appropriate  rule
provision(s) relied upon to terminate or suspend the duty to file reports:
        Rule 12g-4(a)(1)(i)  [X]                   Rule 12h-3(b)(1)(i)  [X]
        Rule 12g-4(a)(1)(ii) [ ]                   Rule 12h-3(b)(1)(ii) [ ]
        Rule 12g-4(a)(2)(i)  [ ]                   Rule 12h-3(b)(2)(i)  [ ]
        Rule 12g-4(a)(2)(ii) [ ]                   Rule 12h-3(b)(2)(ii) [ ]
        Rule 15d-6           [ ]

Approximate number of holders of record as of the certification or notice date:0

        On  September  29,  2000,  the merger of  Epitope,  Inc.,  with and into
Orasure Technologies,  Inc., was consummated. All outstanding shares of Epitope,
Inc.,  capital  stock  were  converted  into  shares of common  stock of Orasure
Technologies,  Inc., in the merger.  As a result,  no shares of capital stock of
Epitope,  Inc.,  remain  outstanding  and the shares of common  stock of Orasure
Technologies,  Inc., are deemed registered under Section 12(g) of the Securities
Exchange  Act of 1934 as  successor  to  Epitope,  Inc.,  pursuant to Rule 12g-3
promulgated thereunder.

                                      -1-
<PAGE>

        Pursuant to the  requirements  of the  Securities  Exchange Act of 1934,
Orasure Technologies, Inc., has caused this certification/notice to be signed on
its behalf by the undersigned duly authorized person.



Date:  October 2, 2000        By:    /s/ Charles E. Bergeron
                              Name:  Charles E. Bergeron
                              Title: Vice President and Chief Financial Officer
                                     of Orasure Technologies, Inc., a Delaware
                                     corporation, successor to Epitope, Inc., an
                                     Oregon corporation


                                      -2-


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission